Experimental vaccine aims to shrink colorectal tumors before surgery

NCT ID NCT06692959

Terminated Disease control Sponsor: University of Southampton Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a vaccine called PD1-Vaxx given before surgery to people with a specific type of colorectal cancer (MSI-high). The goal was to see if the vaccine could shrink tumors, measured by how many cancer cells remained after treatment. Only 3 people took part, and the study was stopped early, so we don't have clear answers yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1 vaccine (PD1-Vaxx)
What this could lead to: If it works, this could point toward a way to shrink tumors before surgery in certain colorectal cancers.
What could go wrong: This was a very early, small trial that was terminated early with only 3 participants, so results are limited and may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

St John of God Subiaco Hospital

Perth, Western Australia, Australia
The Queen Elizabeth Hospital

Adelaide, South Australia, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.